PhotoCure ASA (FRA:PHS) Change In Receivables: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PHS PhotoCure ASA FRA:PHS
71 GF Score
Price €5.20
GF Value €6.29
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Change In Receivables?

PhotoCure ASA FRA:PHS +0.19% 71 Change In Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:PHS with a GF Score™ of 71/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA's change in receivables for the quarter that ended in Mar. 2026 was €0.00 Mil. It means PhotoCure ASA's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

PhotoCure ASA's change in receivables for the fiscal year that ended in Dec. 2025 was €-0.97 Mil. It means PhotoCure ASA's Accounts Receivable increased by €0.97 Mil from Dec. 2024 to Dec. 2025 .

PhotoCure ASA's Accounts Receivable for the quarter that ended in Mar. 2026 was €18.24 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PhotoCure ASA's Days Sales Outstanding for the three months ended in Mar. 2026 was 70.22.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PhotoCure ASA's liquidation value for the three months ended in Mar. 2026 was €14.06 Mil.

PhotoCure ASA  (FRA:PHS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PhotoCure ASA's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=18.236/23.698*91
=70.22

2. In Ben Graham's calculation of liquidation value, PhotoCure ASA's accounts receivable are only considered to be worth 75% of book value:

PhotoCure ASA's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=17.257-18.639+0.75 * 18.236+0.5 * 3.532
=14.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Change In Receivables Related Terms

PhotoCure ASA Change In Receivables Historical Data

* Premium members only.

The historical data trend for PhotoCure ASA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Change In Receivables Chart

PhotoCure ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.49 -0.08 -1.05 -1.26 -0.97

PhotoCure ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PHS
71GF Score
PhotoCure ASA FRA:PHS
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhotoCure ASA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.00 Mil mean?
PhotoCure ASA (FRA:PHS) has a Change In Receivables of €0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PhotoCure ASA and its competitors.
Is PhotoCure ASA's Change In Receivables too high?
PhotoCure ASA's current Change In Receivables is €0.00 Mil. Overall, PhotoCure ASA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Change In Receivables compare to ZTS and UTHR?
PhotoCure ASA's Change In Receivables of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PhotoCure ASA and its competitors. PhotoCure ASA's current Change In Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.20 — trading 17.3% below its estimated fair value. The current Change In Receivables is €0.00 Mil. PhotoCure ASA's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Change In Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.20 is trading 17.3% below its estimated GF Value™ of €6.29. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Change In Receivables: €0.00 Mil
  • GF Value™: €6.29 vs. price of €5.20 (17.3% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
71GF Score

Get the complete analysis for FRA:PHS

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.20
Price
€6.29
GF Value